Publications

• Increased FCA Enforcement Targeting PE Firms Expected in 2024
  11 March 2024
  Helen V. Cantwell
  ,
  Courtney M. Dankworth
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Shannon Rose Selden
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Kaitlyn McGill
• Chevron Under Fire: What Healthcare and Life Sciences Investors Should Know
  19 January 2024
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Zoe Jacoby
  ,
  Adriana Kranjac
  ,
  Kaitlyn McGill
• Top 10 Healthcare and Life Sciences Issues to Watch in 2024
  4 January 2024
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Kim T. Le
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Ilya Balabanovsky
  ,
  Michael L. Cederblom
  ,
  Margaret Howard
  ,
  Chaim Lapp
  ,
  Hannah R. Levine
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
• CMS Announces First Ten Medicare Part D Drugs Subject to Price Negotiations
  6 October 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Michael L. Cederblom
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• 2023 Private Equity Midyear Outlook
  27 July 2023
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Dominic Blaxill
  ,
  Joe Binder
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Andrew J. Ceresney
  ,
  Jeffrey P. Cunard
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Andrew Ford
  ,
  Andrew J. Gershon
  ,
  Mark P. Goodman
  ,
  Jyotin Hamid
  ,
  Ted Hassi
  ,
  Morgan J. Hayes
  ,
  Emily F. Huang
  ,
  Peter J. Irwin
  ,
  Eric T. Juergens
  ,
  Robert B. Kaplan
  ,
  Rafael Kariyev
  ,
  Meir D. Katz
  ,
  M. Natasha Labovitz
  ,
  Maurizio Levi-Minzi
  ,
  Andrew M. Levine
  ,
  Sidney P. Levinson
  ,
  Jonathan F. Lewis
  ,
  Timothy McIver
  ,
  Franklin L. Mitchell
  ,
  Maura Kathleen Monaghan
  ,
  Edwin Northover
  ,
  Brett M. Novick
  ,
  Marc Ponchione
  ,
  Julie M. Riewe
  ,
  Shannon Rose Selden
  ,
  Steven J. Slutzky
  ,
  Thomas Smith
  ,
  Kristin A. Snyder
  ,
  J. Michael Snypes, Jr.
  ,
  Patrick Taylor
  ,
  Ramya S. Tiller
  ,
  Patricia Volhard
  ,
  Richard Ward
  ,
  Erica S. Weisgerber
  ,
  Alison E. Buckley-Serfass
  ,
  Brett Adam Bush
  ,
  Zhiyan Cao
  ,
  Robert T. Dura
  ,
  Stuart Hammer
  ,
  Megan McGuiggan
  ,
  Sheena Paul
  ,
  Tricia Bozyk Sherno
  ,
  Ulysses Smith
  ,
  Jacob W. Stahl
  ,
  Sergio Torres
  ,
  Jennifer Wheater
  ,
  Elie J. Worenklein
  ,
  Adam Aukland-Peck
  ,
  Colleen B. Bernaiche
  ,
  Charles Cartiglia
  ,
  Paul Eastham
  ,
  Jay E. Evans
  ,
  Sara Ewad
  ,
  Christopher Gossage
  ,
  Camila Isern
  ,
  Yiran Ji
  ,
  Maryam Kanna
  ,
  Rekha Korlipara
  ,
  Adriana Kranjac
  ,
  Samuel D. Krawiecz
  ,
  Harshil Mehta
  ,
  Gianni Pizzitola
  ,
  Stanley G. Seckler
  ,
  Sheng Shao
  ,
  Massy Vainshtein
  ,
  Kimberly Anker
• New York Seeks Review and Approval Authority over Certain Healthcare Transactions
  7 March 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Hannah R. Levine
  ,
  Michael L. Cederblom
• Proceed with Caution: Online Tracking Technologies Pose HIPAA Compliance Risks
  2 March 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Hannah R. Levine
  ,
  Michael L. Cederblom
• Top 15 Healthcare and Life Sciences Issues to Watch in 2023
  9 January 2023
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Elie J. Worenklein
  ,
  Samuel J. Allaman
  ,
  Adam Aukland-Peck
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Adam C. Saunders
  ,
  Adrian St. Francis
  ,
  Emily G. Dennan
  ,
  Michael L. Cederblom
  ,
  Micah A. Rubin
• Implications of the Inflation Reduction Act for Investors in Life Sciences Companies
  November 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
  ,
  Michael L. Cederblom
• Private Equity Report Fall 2022, Vol 22, No 3
  November 2022
  Andrew L. Bab
  ,
  Sally Bergmann Hardesty
  ,
  Michael Bolotin
  ,
  Jennifer L. Chu
  ,
  Erin Cleary
  ,
  Matthew Dickman
  ,
  Gregory V. Gooding
  ,
  Mark P. Goodman
  ,
  Gareth Hughes
  ,
  Mark Johnson
  ,
  Meir D. Katz
  ,
  Henry Lebowitz
  ,
  Maurizio Levi-Minzi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kevin M. Schmidt
  ,
  Scott B. Selinger
  ,
  Ramya S. Tiller
  ,
  Zhiyan Cao
  ,
  Caroline P. Geiger
  ,
  Kim T. Le
  ,
  Samuel Fung
  ,
  Jin-Hyuk Jang
  ,
  David Deutsch
  ,
  Tigist Kassahun
  ,
  Hannah R. Levine
  ,
  Keith J. Slattery
  ,
  Sergio Torres
  ,
  Dominique Trudelle
  ,
  Hadel Alfagir
  ,
  Michael L. Cederblom
  ,
  David N. Simpser
• New York’s Adult Survivors Act to Take Effect on November 24, 2022
  22 November 2022
  Helen V. Cantwell
  ,
  Mark P. Goodman
  ,
  Jyotin Hamid
  ,
  Mary Beth Hogan
  ,
  Arian M. June
  ,
  Tricia Bozyk Sherno
• Dealmaking Implications of California’s New Healthcare Cost Monitoring Law
  19 August 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Recent SCOTUS Decisions Impacting Healthcare
  3 August 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
• FTC Sharpens Focus on Private Equity
  17 June 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Kim T. Le
  ,
  Leah Martin
  ,
  Adam C. Saunders
• California Poised to Grant Attorney General Broad Approval Authority over Healthcare Transactions
  16 June 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Texas Federal Judge Sides with Providers in “No Surprises Act” Ruling
  1 March 2022
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kim T. Le
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Adriana Kranjac
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• The Supreme Court TransUnion Case: Part 2—What It Means for Efforts to Defeat Class Certification?
  9 July 2021
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  Jacob W. Stahl
  ,
  Adam Aukland-Peck
  ,
  Benjamin Leb
• The American Rescue Plan Act of 2021: Implications for Healthcare and Life Sciences Companies
  12 March 2021
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Benjamin Leb
• Proposed Elimination of Medicaid Rebate Cap Could Negatively Impact Innovator Pharmaceutical Industry
  11 February 2021
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Biden Takes Aim at Trump Administration Healthcare Policies
  2 February 2021
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Consolidated Appropriations Act: Implications for Healthcare and Life Sciences Companies
  30 December 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• The Trump Administration’s Final Drug Pricing Hurrah—Will It Last?
  24 November 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• COVID-19 Vaccines: FDA Regulatory Timeline and Next Steps Prior to Widespread Distribution
  20 November 2020
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Kevin Rinker
  ,
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jennifer L. Chu
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Federal Government Shines Spotlight on Speaker Programs
  20 November 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• The Potential Impact of a Biden Administration on Life Sciences, Healthcare, and Consumer Product Companies and Investors
  2 November 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Trump’s Newest Drug Pricing Executive Order: Still Much More Bark than Bite
  16 September 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Senate Subcommittee Report Highlights Money Laundering and Sanctions Risks in the Art Industry
  27 August 2020
  Mark P. Goodman
  ,
  Satish M. Kini
  ,
  Andrew M. Levine
  ,
  William H. Taft V
• HHS Announces Additional CARES Act Funding for Qualifying Providers
  4 August 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Kim T. Le
  ,
  Melissa Runsten
• Trump’s New Drug Pricing Executive Orders: Much More Bark Than Bite
  29 July 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• HHS Issues Additional Guidance on Qualifications for CARES Act Funding
  8 May 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Appropriations for Healthcare Providers Related to COVID-19
  30 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• New Appropriation for Healthcare Providers
  24 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Announces Additional Funding for Healthcare Providers Impacted by COVID-19
  23 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Distributing $30 Billion in Grants to Medicare Providers
  10 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CMS Announces Intent to Provide $30 Billion to Medicare Providers
  9 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Update Regarding Public Health and Social Services Emergency Fund
  6 April 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The Federal Government Throws a Lifeline to Medicare Providers and Suppliers
  30 March 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CARES Act: Implications for Healthcare and Life Science Companies and Investors
  27 March 2020
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• COVID-19: CMS Expands Medicare Coverage for Telehealth Services amid Public Health Emergency
  20 March 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• COVID-19: FDA Developments and Legal Considerations for Healthcare and Life Science Companies and Investors
  17 March 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Suchita Mandavilli Brundage
  ,
  Melissa Runsten
• Ninth Circuit Decision Increases Risk of RICO Economic Loss Claims Against Pharmaceutical Manufacturers and Highlights Evolving Circuit Split
  6 March 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  J. Robert Abraham
• What the Bipartisan Budget Agreement Means for the Healthcare Industry and Life Sciences Companies
  23 December 2019
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Leah Martin
• Delaware Court of Chancery Sustains Failure to Monitor Caremark Claim
  22 October 2019
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jonathan R. Tuttle
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• Life Science Leader: From Lab To Lawsuit: Litigation Risks In Pharma-Licensing Agreements
  2 January 2019
  Life Science Leader
  Mark P. Goodman
  ,
  Henry Lebowitz
• Affordable Care Act Likely to Survive Latest Challenge
  19 December 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• How Life Sciences Companies Can Prepare For Legal And PR Crises
  13 December 2018
  Law360
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• How Life Sciences Cos. Can Prepare For Legal And PR Crises
  December 13, 2018
  Law360
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• Medical Device Cybersecurity Report Advancing Coordinated Vulnerability Disclosure
  4 December 2018
  Luke Dembosky
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Managing the Minefield: How Life Sciences Companies Can Be Prepared for Legal and Public Relations Crises
  30 November 2018
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The 2018 Elections: Winners and Losers in the Healthcare Ecosystem
  9 November 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• CMS’ Proposed Part B Price Controls: Hurdles and Unintended Consequences
  5 November 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• CMS’ Proposed Rule Regarding Disclosure of Drug “List Prices” in Television Ads: Needed Transparency or Recipe for Confusion?
  23 October 2018
  Andrew L. Bab
  ,
  David H. Bernstein
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Jared I. Kagan
  ,
  Melissa Runsten
• The White House’s Drug Pricing “Blueprint”
  18 May 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• DOJ Memorandum Addressing Agency Guidance
  9 March 2018
  Compliance & Enforcement
  Courtney M. Dankworth
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• DOJ Memorandum Addressing Agency Guidance
  8 March 2018
  Courtney M. Dankworth
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• The Latest on the Trump Administration’s Drug Pricing Initiatives
  21 February 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• DOJ Creates Potential Opening For Early Dismissal of False Claims Act Suits
  1 February 2018
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• T.H. v. Novartis: Implications for Companies That Have Sold or Are Considering Selling the Rights to Innovator Drugs
  19 January 2018
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
• How Tax Reform and Other Recent Developments Could Impact the Healthcare Industry
  20 December 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Peter A. Furci
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• New Public and Private Efforts to Contain Healthcare Costs: What it Means for the Healthcare Industry
  20 December 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• Law360: How Tax Reform Could Impact the Health Care Industry
  15 November 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Peter A. Furci
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• How Tax Reform Could Impact The Health Care Industry
  13 November 2017
  Law360
  Jennifer L. Chu
  ,
  Peter A. Furci
  ,
  Mark P. Goodman
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The “Tax Cuts and Jobs Act” – How It Impacts the Healthcare Industry
  7 November 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Gary M. Friedman
  ,
  Peter A. Furci
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Where Does Healthcare Reform Stand?
  31 October 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• How Section 1332 Waivers Could Impact Health Care Reform
  24 July 2017
  Law 360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Health Care Winners And Losers From The Better Care Act
  29 June 2017
  Law 360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• The “Better Care Act”: Winners and Losers in the Healthcare Industry
  28 June 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• The Senate’s Healthcare Bill – What’s In It?
  28 June 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Finally A Health Care Reform Plan Passes the House – What’s in the Bill and What it Means for the Healthcare Industry
  5 May 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Shining A Light On GOP Plan For Health Care Reform
  7 March 2017
  Law360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Just a Bit of Clarity – Recent Developments Shine Some Light on Trump and GOP Plans for Healthcare Reform
  27 February 2017
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• The Outlook For The Pharmaceutical Industry Under Trump
  12 January 2017
  Law360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• The Outlook On Drug Pricing: At What Cost?
  14 December 2016
  Law360
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• Still in the Waiting Room: Outlook for the Healthcare Industry Under the Trump Administration
  15 November 2016
  Andrew L. Bab
  ,
  Jennifer L. Chu
  ,
  Gary M. Friedman
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
• A Walk in the Park Shouldn’t Lead to Jail Time: Recent Decisions Explain Why Incarceration Is Never Appropriate for ‘Responsible Corporate Officers’ Who Lack Criminal Intent
  7 October 2016
  Bloomberg BNA Pharmaceutical Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Helen V. Cantwell
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• New Federal Ransomware Guidance
  19 July 2016
  Luke Dembosky
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  David Sarratt
• FDA’s New Guidance On Cybersecurity For Medical Devices: Important Lessons For The Entire Healthcare Industry
  25 April 2016
  Bloomberg BNA Health IT Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  David Sarratt
  ,
  Jacob W. Stahl
• Florida Court Dismisses Data Breach Lawsuit for Lack of Standing
  29 February 2016
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Elliot Greenfield
  ,
  David Sarratt
• FDA Publishes Guidance on Postmarket Cybersecurity Risk Management for Medical Device Manufacturers
  25 January 2016
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  David Sarratt
  ,
  Jacob W. Stahl
• It’s A Hard-Knock Life: The Rough-And-Tumble Fight Over Orphan Drug Pricing
  12 January 2016
  American Bar Association
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• The “Yates Memorandum”: Has DOJ Really Changed Its Approach To White Collar Criminal Investigations and Individual Prosecutions?
  15 September 2015
  Helen V. Cantwell
  ,
  Matthew E. Fishbein
  ,
  Bruce E. Yannett
  ,
  David A. O'Neil
  ,
  Paul R. Berger
  ,
  Courtney M. Dankworth
  ,
  Eric Dinallo
  ,
  Mark P. Goodman
  ,
  Mary Beth Hogan
  ,
  Robert B. Kaplan
  ,
  Satish M. Kini
  ,
  Andrew M. Levine
  ,
  Michael B. Mukasey
  ,
  Jim Pastore
  ,
  Colby A. Smith
  ,
  Jonathan R. Tuttle
  ,
  Erich O. Grosz
  ,
  David Sarratt
• Avoiding And Defeating Securities Fraud Actions Against Clinical-Stage Biopharmaceutical Companies
  10 July 2015
  Bloomberg BNA Life Sciences Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  William H. Taft V
  ,
  Jacob W. Stahl
• First Circuit Holds That Federal Law Preempts State-Law Claims Involving a Branded Drug Label
  4 March 2015
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  J. Robert Abraham
• Ninth Circuit Affirms District Court Order to Unwind Hospital Merger
  13 February 2015
  Gary W. Kubek
  ,
  Mark P. Goodman
  ,
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Kristin D. Kiehn
  ,
  Erica S. Weisgerber
• Breaking Ranks: Garlock Reaches Unprecedented Deal with Future Claims Representative on Value of Trust for Asbestos Claims
  21 January 2015
  Mark P. Goodman
  ,
  M. Natasha Labovitz
  ,
  Maura Kathleen Monaghan
  ,
  Shannon Rose Selden
• Second Circuit Restores Teeth to Insider Trading Personal Benefit Requirement
  11 December 2014
  Paul R. Berger
  ,
  Helen V. Cantwell
  ,
  Eric Dinallo
  ,
  Matthew E. Fishbein
  ,
  Mark P. Goodman
  ,
  Matthew E. Kaplan
  ,
  Robert B. Kaplan
  ,
  Andrew M. Levine
  ,
  Jonathan R. Tuttle
  ,
  Bruce E. Yannett
• Food For Thought: Corporate Executives On Notice That DOJ Will Seek To Hold Them Criminally Liable for Contaminated Food Outbreaks And Product Failures
  14 November 2014
  Bloomberg BNA’s White Collar Crime Report
  Helen V. Cantwell
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• It’s A Hard-Knock Life: The Rough-And-Tumble Fight Over Orphan Drug Pricing
  14 November 2014
  Bloomberg BNA’s Pharmaceutical Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• The Shift in Litigation Risks When U.S. Companies Go Public
  November 2014
  Transaction Advisors
  Mark P. Goodman
  ,
  Shannon Rose Selden
• The Shift in Litigation Risks When U.S. Companies Go Public
  Fall 2014
  Mark P. Goodman
  ,
  Shannon Rose Selden
• DOJ Proposal Shows Focus on Individuals in Corporate Crime
  30 September 2014
  Law360
  Helen V. Cantwell
  ,
  Matthew E. Fishbein
  ,
  Mark P. Goodman
  ,
  Mary Beth Hogan
  ,
  Andrew M. Levine
  ,
  Jonathan R. Tuttle
  ,
  Bruce E. Yannett
  ,
  Kristin D. Kiehn
  ,
  David Sarratt
  ,
  Jacob W. Stahl
• Provocative DOJ Proposal Aims to Hold Financial Services Executives Criminally Liable, Even Absent Criminal Intent
  22 September 2014
  Bruce E. Yannett
  ,
  Mary Beth Hogan
  ,
  Helen V. Cantwell
  ,
  Matthew E. Fishbein
  ,
  Mark P. Goodman
  ,
  Andrew M. Levine
  ,
  Jonathan R. Tuttle
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• Compliance Corner: The Clock Is Ticking: 60-Day Rule and FCA Liability for Overpayments
  17 September 2014
  Bloomberg BNA’s Health Care Fraud Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• FDA Issues Proposed Guidance on Social Media and Internet Communications for Pharmaceutical and Medical Device Manufacturers
  27 June 2014
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• Vicarious Criminal Liability in the Executive Suite for Problems on the Manufacturing Floor
  4 April 2014
  Bloomberg BNA’s Pharmaceutical Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  Jacob W. Stahl
• Court Rules that Due to Misrepresentations by Plaintiffs’ Firms, Garlock’s Settlement History Does Not Accurately Represent Its Actual Asbestos Liability
  February/March 2014
  Pratt’s Journal of Bankruptcy Law.
  Mark P. Goodman
  ,
  M. Natasha Labovitz
  ,
  Maura Kathleen Monaghan
• Court Rules That Due to Misrepresentations by Plaintiffs’ Firms, Garlock’s Settlement History Does Not Accurately Represent Its Actual Asbestos Liability
  21 January 2014
  Maura Kathleen Monaghan
  ,
  Mark P. Goodman
  ,
  M. Natasha Labovitz
• Handling State AG Parens Patriae Actions Now That the Supreme Court Has Rejected Federal Court Removal
  21 January 2014
  Mark P. Goodman
  ,
  John S. Kiernan
  ,
  Maura Kathleen Monaghan
  ,
  Erica S. Weisgerber
• Enforcement without Guidance: The FDA’s Policing of Online Pharmaceutical Advertisements and Communications
  20 December 2013
  Bloomberg BNA Pharmaceutical Law & Industry Report
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• Supreme Court to Review “Fraud on the Market” Presumption of Reliance in Securities Class Actions
  21 November 2013
  Mark P. Goodman
  ,
  John S. Kiernan
  ,
  Shannon Rose Selden
  ,
  William H. Taft V
  ,
  Gary W. Kubek
  ,
  Maeve O'Connor
  ,
  Colby A. Smith
• Multi-Jurisdictional Criminal Investigations Pose Many Challenges
  18 November 2013
  New York Law Journal
  Antoine F. Kirry
  ,
  Mark P. Goodman
  ,
  Frederick T. Davis
• Did the Third Circuit Just Impose a Proof-of-Purchase Requirement in Consumer Product Class Actions?
  6 August 2013
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
• Supreme Court Expands “Impossibility” Preemption to Design Defect Claims against Generic Drug Manufacturers
  26 June 2013
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
  ,
  J. Robert Abraham
• SEC Enforcement Action Targets Advisers to Private Equity Funds
  15 March 2013
  Paul R. Berger
  ,
  Kenneth J. Berman
  ,
  Jonathan R. Tuttle
  ,
  Eric Dinallo
  ,
  Mark P. Goodman
  ,
  Michael P. Harrell
  ,
  Shannon Rose Selden
• Fund Directors Charged in Recent SEC Enforcement Case Targeting Valuation
  14 December 2012
  Paul R. Berger
  ,
  Jonathan R. Tuttle
  ,
  Eric Dinallo
  ,
  Mark P. Goodman
  ,
  Shannon Rose Selden
• Second Circuit Concludes Truthful Off-Label Promotion Is Not Unlawful: Free Speech, But Not A Free Pass (Yet)
  5 December 2012
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Andrew M. Levine
  ,
  Kristin D. Kiehn
• U.S. Enforcement Agencies Issue Extensive New FCPA Guidance
  15 November 2012
  Bruce E. Yannett
  ,
  Mark P. Goodman
  ,
  Andrew M. Levine
  ,
  Erich O. Grosz
  ,
  Paul R. Berger
  ,
  Colby A. Smith
  ,
  Jonathan R. Tuttle
  ,
  Philip Rohlik
• GSK's $3 Billion Settlement Reflects Continued Expansion In Scope Of Pharma Plea Agreements
  August 2012
  Rx Compliance Report
  Kristin D. Kiehn
  ,
  Maura Kathleen Monaghan
  ,
  Mark P. Goodman
• GSK $3 Billion Settlement Reflects Continued Expansion in Scope of Pharma Plea Agreements
  9 July 2012
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
• Supreme Court Upholds 2010 Patient Protection and Affordable Care Act
  29 June 2012
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
• An Unprecedented Settlement For FDCA Violation
  22 May 2012
  Law360
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
• Abbott Settlement Includes Unprecedented Term of Probation, Mandatory Compliance Measures
  10 May 2012
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
• President Obama Signs the STOCK Act
  4 April 2012
  Eric Dinallo
  ,
  Mark P. Goodman
  ,
  Jennifer R. Cowan
• Defending Corporations and Individuals in Government Investigations
  2011 edition
  Thomson West
  Mark P. Goodman
• Supreme Court Rules in Two Pharma Cases
  29 June 2011
  Anne E. Cohen
  ,
  Andrew L. Bab
  ,
  Kevin Rinker
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kristin D. Kiehn
• Bruesewitz v. Wyeth: Express Preemption Returns to the Fore
  23 February 2011
  Maura Kathleen Monaghan
  ,
  Roger E. Podesta
  ,
  Mark P. Goodman
  ,
  Anne E. Cohen
  ,
  Mary Beth Hogan
  ,
  Kristin D. Kiehn
• U.S. Securities and Exchange Commission Launches Probe of Financial Institution Dealings with Sovereign Wealth Funds
  18 January 2011
  Paul R. Berger
  ,
  Bruce E. Yannett
  ,
  Eric Dinallo
  ,
  Mark P. Goodman
  ,
  Jonathan R. Tuttle
• FCPA Update
  December 2010, Vol. 2, No. 5
  Paul R. Berger
  ,
  Bruce E. Yannett
  ,
  Mark P. Goodman
• The Private Equity Report
  Fall 2010
  Franci J. Blassberg
  ,
  Guy Lewin-Smith
  ,
  Edwin Northover
  ,
  E. Drew Dutton
  ,
  Gary W. Kubek
  ,
  Kyra K. Bromley
  ,
  Marcia L. MacHarg
  ,
  Paul S. Bird
  ,
  Jonathan E. Levitsky
  ,
  Geoffrey Kittredge
  ,
  Mark P. Goodman
  ,
  Erica S. Weisgerber
  ,
  Jeffrey J. Rosen
  ,
  Peter A. Furci
• U.S. Attorney’s Office for the Southern District of New York and U.S. Securities and Exchange Commission Investigate Massive Insider Trading Ring
  22 November 2010
  Mark P. Goodman
  ,
  Anne E. Cohen
  ,
  Helen V. Cantwell
  ,
  Jonathan R. Tuttle
• The Private Equity Report
  Summer 2009
  Franci J. Blassberg
  ,
  Katherine Ashton
  ,
  Geoffrey P. Burgess
  ,
  Michael Diz
  ,
  Mark P. Goodman
  ,
  Richard F. Hahn
  ,
  Michael P. Harrell
  ,
  Satish M. Kini
  ,
  Paul L. Lee
  ,
  Jonathan F. Lewis
  ,
  Gregory J. Lyons
  ,
  Pierre Maugüé
  ,
  Jeffrey J. Rosen
• Wyeth v Levine: The Road Ahead
  3 April 2009
  Scrip World Pharmaceutical News
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
• Wyeth v Levine: The Road Ahead
  26 March 2009
  ScripNews.com
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
• Courts Refuse to Give Full Faith and Credit to Nationwide Products Settlement
  11 March 2009
  Mark P. Goodman
  ,
  John S. Kiernan
• Wyeth v. Levine: Not the End of Preemption and Not the End of the World
  10 March 2009
  Maura Kathleen Monaghan
  ,
  Roger E. Podesta
  ,
  Mark P. Goodman
  ,
  Anne E. Cohen
  ,
  Mary Beth Hogan
• The Private Equity Report
  Summer 2004
  Franci J. Blassberg
  ,
  Carl Micarelli
  ,
  Mark P. Goodman
  ,
  David F. Hickok
  ,
  Richard Ward
  ,
  Rebecca F. Silberstein
  ,
  Marcia L. MacHarg
  ,
  Gregory V. Gooding
• The Private Equity Report
  Fall 2001
  Mark P. Goodman
  ,
  Franci J. Blassberg
  ,
  William D. Regner
  ,
  Paul D. Brusiloff
  ,
  Adele M. Karig
  ,
  John M. Vasily
  ,
  Woodrow W. Campbell, Jr.
  ,
  Margaret Andrews Davenport
  ,
  Andrew N. Berg
• Funding in Focus: When Healthcare Licensing Goes Wrong
  Issue Seven, 2018
  Mark P. Goodman
  ,
  Henry Lebowitz
  ,
  Megan K. Bannigan
  ,
  Jacob W. Stahl